<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-144778" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pityriasis Lichenoides Et Varioliformis Acuta (PLEVA)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Teklehaimanot</surname>
            <given-names>Fayven</given-names>
          </name>
          <aff>Michigan State College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gade</surname>
            <given-names>Anita</given-names>
          </name>
          <aff>Stamford Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rubenstein </surname>
            <given-names>Richard</given-names>
          </name>
          <aff>Medical College of Virginia, Richmond, VA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Fayven Teklehaimanot declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anita Gade declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Richard Rubenstein declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-144778.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pityriasis lichenoides encompasses a group of inflammatory cutaneous disorders known as pityriasis lichenoides chronica (PLC), pityriasis lichenoides et varioliformis acuta (PLEVA), and febrile ulceronecrotic Mucha-Habermann disease (a subtype of PLEVA). PLEVA is a relatively benign cutaneous disorder of unclear origin that affects children and young adults. Patients present with a spontaneous eruption of erythematous macules that evolve into papules, rapidly undergoing hemorrhagic necrosis and ulceration. The disease tends to wax and wane with complete resolution, varying in weeks to years. This activity describes the pathophysiology and clinical presentation of PLEVA and the importance of the interprofessional team in recognizing and managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the pathophysiology of pityriasis lichenoides et varioliformis acuta.</p></list-item><list-item><p>Assess&#x000a0;the presentation of pityriasis lichenoides et varioliformis acuta.</p></list-item><list-item><p>Evaluation&#x000a0;the treatment and management options for pityriasis lichenoides et varioliformis acuta.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144778&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144778">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-144778.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pityriasis lichenoides et varioliformis acuta (PLEVA), also known as&#x000a0;Mucha-Habermann disease, is an uncommon cutaneous inflammatory rash characterized by diffuse red-brown papules in various stages with a mica-like scale on more established lesions. The papules may progress to form vesicles, pustules, and ulcers, and these lesions can be associated with pruritus or a burning sensation. PLEVA favors the trunk and proximal extremities, especially in the flexural regions. This rash tends to relapse and remit with variable duration, sometimes lasting up to years.<xref ref-type="bibr" rid="article-144778.r1">[1]</xref>&#x000a0;See <bold>Image.</bold>&#x000a0;Ulcerated Pityriasis&#x000a0;Lichenoides&#x000a0;Et&#x000a0;Varioliformis&#x000a0;Acuta on the arm.</p>
      </sec>
      <sec id="article-144778.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiology of PLEVA is not known. However, various hypotheses have been noted in the literature, including an atypical immune response to infections, an inflammatory reaction to medications, and a lymphoproliferative disorder. In support of these hypotheses, there have been cases reported of PLEVA following infections with pathogens such as Epstein-Barr virus, human immunodeficiency virus (HIV), varicella-zoster virus, Toxoplasma gondii, Group A streptococcus, and herpes simplex virus type 2.<xref ref-type="bibr" rid="article-144778.r1">[1]</xref><xref ref-type="bibr" rid="article-144778.r2">[2]</xref>&#x000a0;Additionally, PLEVA has been found to erupt in response to receiving the human papillomavirus, influenza, tetanus, measles, mumps, and rubella (MMR) vaccinations.<xref ref-type="bibr" rid="article-144778.r3">[3]</xref><xref ref-type="bibr" rid="article-144778.r4">[4]</xref><xref ref-type="bibr" rid="article-144778.r5">[5]</xref><xref ref-type="bibr" rid="article-144778.r6">[6]</xref>&#x000a0;Due to the risk of development of lymphoma and clinical similarity to lymphomatoid papulosis, the hypothesis regarding lymphoproliferation and T cell dyscrasia must be considered. PLEVA may also develop following certain medications, including atezolizumab, pembrolizumab, and topical diphenylcyclopropenone.<xref ref-type="bibr" rid="article-144778.r7">[7]</xref><xref ref-type="bibr" rid="article-144778.r8">[8]</xref></p>
      </sec>
      <sec id="article-144778.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence, prevalence, and risk factors of PLEVA are unknown. The disease does not discriminate by race or gender and mainly affects children and young adults, with a slight male predominance.<xref ref-type="bibr" rid="article-144778.r1">[1]</xref></p>
      </sec>
      <sec id="article-144778.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Due to the ambiguity of the etiology of PLEVA, there are various theories regarding the pathophysiology. Some patients experience deposition of IgM and C3 in the skin lesions and elevated immune complexes in the serum, indicating immune complex or hypersensitivity reaction.<xref ref-type="bibr" rid="article-144778.r9">[9]</xref>&#x000a0;Despite these findings, PLEVA is not considered a vasculitic phenomenon, as fibrin is lacking in the walls of vessels, and thrombi are absent in the lumen. Other lesions exhibit a cell-mediated mechanism with cytotoxic T-cell collections in the dermis, along with decreases in Langerhans cells and the CD4/CD8 ratio.<xref ref-type="bibr" rid="article-144778.r9">[9]</xref>&#x000a0;Additionally, amplifying T cell receptor genes via polymerase chain reaction (PCR) has shown T cell clonality within the lymphocytic infiltrates, suggesting lymphoproliferation with neoplastic potential.<xref ref-type="bibr" rid="article-144778.r1">[1]</xref></p>
      </sec>
      <sec id="article-144778.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>A definitive diagnosis of PLEVA requires a thorough history, physical exam, and skin biopsy due to many diseases with similar clinical presentations. Many histopathologic findings for PLEVA confirm the diagnosis.<xref ref-type="bibr" rid="article-144778.r10">[10]</xref>&#x000a0;Epidermal findings include spongiosis, dyskeratosis, parakeratosis, acanthosis, intraepidermal vesicles, and necrosis.<xref ref-type="bibr" rid="article-144778.r1">[1]</xref>&#x000a0; Dermal findings include edema,&#x000a0;wedge-shaped superficial and deep dermal lymphohistiocytic inflammatory infiltrate, lymphocyte and erythrocyte extravasation, subepidermal vesicles, and dermal sclerosis.<xref ref-type="bibr" rid="article-144778.r9">[9]</xref>&#x000a0;Vascular findings are notable for papillary dermis blood vessel dilation and engorgement with endothelial proliferation, vascular congestion, and erythrocyte extravasation.<xref ref-type="bibr" rid="article-144778.r1">[1]</xref>&#x000a0;Dermatoscopic findings for PLEVA have been reported in the literature and include a ring of pinpoint vasculature, brown amorphous areas, white scale, and focal melanin deposition within the stratum corneum.<xref ref-type="bibr" rid="article-144778.r11">[11]</xref>&#x000a0;Early-phase lesions have crusted brown and amorphous areas, while late-phase lesions contain a central white patch. The lesions are encircled in both phases by a ring of pinpoint or linear vascular structures.<xref ref-type="bibr" rid="article-144778.r12">[12]</xref></p>
      </sec>
      <sec id="article-144778.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough history and physical exam can have significant value in the diagnosis of PLEVA due to the nature of the disease and uncertainty regarding its etiology. It is in the provider's best interest to ask patients about recent vaccinations, illnesses, and medications. On physical exam, PLEVA manifests as an abrupt eruption of 10-50 erythematous macules that quickly form into inflammatory papules with a fine scale. As the rash progresses, the scale remains attached centrally but lifts peripherally. The papules may then evolve into pityriasis lichenoides chronica lesions or&#x000a0;undergo hemorrhagic necrosis and become ulcerated, forming the appearance of red-brown crusts, with possible post-inflammatory hyper- and hypopigmentation.<xref ref-type="bibr" rid="article-144778.r9">[9]</xref> In rare cases, darker-skinned patients may experience diffuse macular hypopigmentation instead of the classic papular morphology.<xref ref-type="bibr" rid="article-144778.r13">[13]</xref><xref ref-type="bibr" rid="article-144778.r14">[14]</xref>&#x000a0;PLEVA may be asymptomatic or present with burning and pruritus. The polymorphous lesions tend to favor the trunk and flexural surfaces of the proximal extremities, but a diffuse presentation is not uncommon. PLEVA often occurs in a remitting and relapsing nature that may last several weeks to years before resolution.<xref ref-type="bibr" rid="article-144778.r15">[15]</xref>&#x000a0;Although rare, febrile ulceronecrotic Mucha-Habermann disease (FUMHD) may follow an existing diagnosis of PLEVA or occur de novo. It is important to be aware of this subtype of PLEVA due to the severity and potential lethality of the disease. Patients affected by FUMHD present with necrotic papules that progress to plaques and large coalescent ulcers. Skin ulceration can be extensive and painful, including oral and genital mucosal.<xref ref-type="bibr" rid="article-144778.r16">[16]</xref>&#x000a0;Common systemic symptoms include high fever, abdominal pain, diarrhea, central nervous system manifestations, joint pain, respiratory complications, and death.<xref ref-type="bibr" rid="article-144778.r16">[16]</xref></p>
      </sec>
      <sec id="article-144778.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Although the diagnosis of PLEVA is mainly clinical and aided by dermatoscopy, a histologic evaluation of lesional skin is imperative due to the numerous differential diagnoses with similar presentations. Punch biopsies are recommended to ensure that the epidermis and dermis can be appropriately evaluated. Immunohistochemical studies can aid in confirming the diagnosis and typically show CD8-positive T lymphocytes and negative CD30 stains (to rule out lymphomatoid papulosis).<xref ref-type="bibr" rid="article-144778.r9">[9]</xref>&#x000a0;Serological studies are not specific for PLEVA, but findings, including leukocytosis, elevated C-reactive protein, and erythrocyte sedimentation rate, can be seen in FUMHD.<xref ref-type="bibr" rid="article-144778.r1">[1]</xref> Other common/useful non-specific tests to diagnose PLEVA by exclusion include toxoplasma Sabin-Feldman dye, heterophile antibody test, antistreptolysin o titers, throat cultures, HIV screening, and rapid plasma reagin test.<xref ref-type="bibr" rid="article-144778.r1">[1]</xref></p>
      </sec>
      <sec id="article-144778.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Due to the benign nature of PLEVA, pharmacologic therapy is unnecessary but may quicken the recovery process and provide relief if the patient is symptomatic. Data regarding treatment for the disease is limited, although various retrospective series and case reports recognize systemic antibiotics or phototherapy as first-line therapies in conjunction with corticosteroids.<xref ref-type="bibr" rid="article-144778.r17">[17]</xref>&#x000a0;Systemic antihistamines may also offer relief from pruritus. Furthermore,&#x000a0;large ulcerations of PLEVA may benefit from local wound care.<xref ref-type="bibr" rid="article-144778.r16">[16]</xref>&#x000a0;Follow-up monitoring is required in aggressive cases of PLEVA with a waxing and waning course.&#x000a0;Antibiotics known for their anti-inflammatory properties, such as doxycycline, minocycline, and erythromycin for children, are most commonly utilized.<xref ref-type="bibr" rid="article-144778.r17">[17]</xref><xref ref-type="bibr" rid="article-144778.r18">[18]</xref>&#x000a0;Antibiotics are continued until the lesions are resolved for up to&#x000a0;3 months, and in some cases, longer. If there is no response, phototherapy is considered.</p>
        <p>Ultraviolet B light is the most common first-line phototherapy, with no significant difference between narrow and broadband ultraviolet B light. Although the long-term effects of phototherapy are unknown, children who received treatment did not experience any early side effects.&#x000a0;In adults, therapy is directed by preference and other existing diseases.<xref ref-type="bibr" rid="article-144778.r17">[17]</xref> Psoralen plus ultraviolet A has been reported as effective in multiple case studies.<xref ref-type="bibr" rid="article-144778.r17">[17]</xref> Ultraviolet A1 has been reported in the literature to aid in the complete resolution of lesions, although it is less accessible and more commonly found in academic centers.<xref ref-type="bibr" rid="article-144778.r19">[19]</xref>&#x000a0;Corticosteroids are commonly utilized as adjunctive therapy, and for patients with refractory disease, methotrexate may be an option.<xref ref-type="bibr" rid="article-144778.r20">[20]</xref><xref ref-type="bibr" rid="article-144778.r21">[21]</xref>&#x000a0;Additional therapies for refractory cases include acitretin, dapsone, and cyclosporine.<xref ref-type="bibr" rid="article-144778.r21">[21]</xref>&#x000a0;In contrast to the self-limited course of PLEVA, febrile ulceronecrotic Mucha-Habermann disease is a life-threatening disease that presents therapeutic challenges.&#x000a0;Many case studies have shown patients with different responses to the same therapeutic approaches, preventing a gold standard treatment from developing. FUMHD may be treated with TNF-a inhibitors such as infliximab due to elevated TNF-a levels reported in a previous pediatric case and success in an adult case.<xref ref-type="bibr" rid="article-144778.r22">[22]</xref><xref ref-type="bibr" rid="article-144778.r23">[23]</xref><xref ref-type="bibr" rid="article-144778.r24">[24]</xref> Further studies, such as randomized control trials, are needed to assess the efficacy of the therapies mentioned optimally.</p>
      </sec>
      <sec id="article-144778.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for&#x000a0;PLEVA includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Langerhans cell histiocytosis</p>
          </list-item>
          <list-item>
            <p>Gianotti-Crost syndrome</p>
          </list-item>
          <list-item>
            <p>Generalized arthropod bite reaction&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Disseminated herpes simplex virus</p>
          </list-item>
          <list-item>
            <p>Varicella Zoster virus&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cutaneous small vessel vasculitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Arthropod bite</p>
          </list-item>
          <list-item>
            <p>Secondary syphilis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Polymorphous light reaction</p>
          </list-item>
          <list-item>
            <p>Generalized folliculitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pityriasis lichenoides chronica</p>
          </list-item>
          <list-item>
            <p>Lymphomatoid papulosis</p>
          </list-item>
          <list-item>
            <p>Lichen planus</p>
          </list-item>
          <list-item>
            <p>Hypopigmented mycosis fungoides</p>
          </list-item>
          <list-item>
            <p>Papular eczematous dermatitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pityriasis rosea</p>
          </list-item>
          <list-item>
            <p>Guttate psoriasis</p>
          </list-item>
          <list-item>
            <p>Urticaria pigmentosa</p>
          </list-item>
          <list-item>
            <p>Exanthematous drug eruption</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-144778.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Although rare, PLEVA may evolve into the potentially lethal variant, febrile ulceronecrotic Mucha-Habermann disease. There have also been reports of PLEVA linked to cutaneous T-cell lymphoma. Otherwise, the prognosis is typically excellent, considering the relatively benign clinical course of PLEVA and the rarity of the associated disorders.<xref ref-type="bibr" rid="article-144778.r22">[22]</xref></p>
      </sec>
      <sec id="article-144778.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Due to the enigmatic nature of PLEVA, misdiagnosis is a common complication. Lymphomatoid papulosis, for example, is a skin disease that mimics PLEVA, but the separation of the&#x000a0;2 must be emphasized because of differences in prognosis. Lymphomatoid papulosis has a significant risk of transforming into a cutaneous malignant lymphoma.&#x000a0;Pityriasis Lichenoides (PL)-like mycosis fungoides (MF), is a rare form of MF that also appears similarly to PL during the clinical inspection.<xref ref-type="bibr" rid="article-144778.r25">[25]</xref>&#x000a0;Although&#x000a0;the histopathological features of PL-like MF are more representative of typical MF, including but not limited to Pautrier&#x02019;s microabscess, haloed lymphocytes, and epidermotropism,&#x000a0;<xref ref-type="bibr" rid="article-144778.r25">[25]</xref>&#x000a0;it&#x000a0;is imperative that histology is utilized when evaluating these patients to distinguish LP and PL-like MF from the various subtypes of PL. Additionally, extensive studies may be warranted if the course of PLEVA has progressed to PLC and is unresponsive to treatment. Although rare, there have been cases reported of CTCL discovered after PLC diagnosis.<xref ref-type="bibr" rid="article-144778.r26">[26]</xref>&#x000a0;In&#x000a0;1 specific case, a pediatric patient was histologically diagnosed with PLC at&#x000a0;8 months and went untreated. He presented to the clinic again at&#x000a0;2 years of age with the development of an indurated plaque, which was confirmed as lymphomatoid papulosis after a second biopsy. The patient again went untreated with the assumption that the rash would spontaneously resolve. With no resolution of the skin disease, the patient was re-evaluated at&#x000a0;4 years old with an additional biopsy, immunostaining, and polymerase chain reaction analysis for clonal TCR gene rearrangement, which confirmed CTCL involvement.<xref ref-type="bibr" rid="article-144778.r26">[26]</xref>&#x000a0;Concerning outward appearance, the ulceronecrotic lesions in PLEVA may lead to alteration in pigmentation of the skin or heal with varioliform scarring. PLEVA can progress into PLC or present in the more fulminant form, FUMHD. The psychological component of PLEVA must not be overlooked due to its diffuse involvement in exposed skin areas.</p>
      </sec>
      <sec id="article-144778.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>In most patients,&#x000a0;PLEVA is a self-resolving, benign skin disease typically lasting a few weeks. Patients and their families should be educated that the disease is not contagious, and if symptoms worsen, reassessment is necessary.</p>
      </sec>
      <sec id="article-144778.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team of clinicians, nurses, and pharmacists should work closely with the patient and family members to obtain a thorough history and physical examination for proper diagnosis. Due to the self-resolving nature of PLEVA, follow-up visits should occur every&#x000a0;3 to&#x000a0;6 months if there is no desire for treatment. Office visits are useful for reevaluating and ensuring no further disease progression or diagnosis change. Patients who choose to receive treatment, such as&#x000a0;antibiotics, phototherapy, or corticosteroids, should be monitored closely to assess efficacy. Nursing can serve as a liaison contact point for the treating clinicians, specialists, and other healthcare providers, providing patient counseling and keeping all parties informed of changes in patient status. The pharmacist can ensure proper dosing and screen for interactions when pharmaceutical care is opted for, reporting any concerns to the nurse of prescribing clinicians. This interprofessional approach yields the best patient outcomes.</p>
      </sec>
      <sec id="article-144778.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144778&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144778">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/pityriasis-lichenoides-et-varioliformis-acuta-pleva/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=144778">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/144778/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=144778">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-144778.s16">
        <fig id="article-144778.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Ulcerated Pityriasis Lichenoides Et Varioliformis Acuta on the arm <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pityriasis-lichenoides-0044__WatermarkedWyJXYXRlcm1hcmtlZCJd" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-144778.s17">
        <title>References</title>
        <ref id="article-144778.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bowers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Warshaw</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Pityriasis lichenoides and its subtypes.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>557</fpage>
            <page-range>557-72; quiz 573-6</page-range>
            <pub-id pub-id-type="pmid">17010734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez Rodr&#x000ed;guez</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Montesinos Villaescusa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jord&#x000e1; Cuevas</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pityriasis lichenoides chronica associated with herpes simplex virus type 2.</article-title>
            <source>Case Rep Dermatol Med</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>737428</fpage>
            <pub-id pub-id-type="pmid">23243523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jastrz&#x00105;b</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Stefaniak</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Hryncewicz-Gw&#x000f3;&#x0017a;d&#x0017a;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nockowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Szepietowski</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Pityriasis Lichenoides et Varioliformis Acuta Triggered by Human Papillomavirus Vaccine: A Case Report and Literature Review.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2021</year>
            <month>Sep</month>
            <day>17</day>
            <volume>101</volume>
            <issue>9</issue>
            <fpage>adv00552</fpage>
            <pub-id pub-id-type="pmid">34515802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castro</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Trindade</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Pedrosa</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Piancastelli</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Pityriasis lichenoides et varioliformis acuta after influenza vaccine.</article-title>
            <source>An Bras Dermatol</source>
            <year>2015</year>
            <season>May-Jun</season>
            <volume>90</volume>
            <issue>3 Suppl 1</issue>
            <fpage>181</fpage>
            <page-range>181-4</page-range>
            <pub-id pub-id-type="pmid">26312710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merlotto</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Bicudo</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>MEA</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Pityriasis lichenoides et varioliformis acuta following anti-tetanus and diphtheria adult vaccine.</article-title>
            <source>An Bras Dermatol</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>259</fpage>
            <page-range>259-260</page-range>
            <pub-id pub-id-type="pmid">32156502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shastry</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ranugha</surname>
                <given-names>PSS</given-names>
              </name>
              <name>
                <surname>Rangappa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sanjaykumar</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pityriasis lichenoides et varioliformis acuta following measles rubella vaccine.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2020</year>
            <season>Jul-Aug</season>
            <volume>86</volume>
            <issue>4</issue>
            <fpage>398</fpage>
            <page-range>398-400</page-range>
            <pub-id pub-id-type="pmid">32474500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seong</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Shon</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DY</given-names>
              </name>
            </person-group>
            <article-title>A Case of Pityriasis Lichenoides et Varioliformis Acuta-Like Eruption Developed after Pembrolizumab Treatment for Invasive Thymoma.</article-title>
            <source>Ann Dermatol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>94</fpage>
            <page-range>94-96</page-range>
            <pub-id pub-id-type="pmid">33911821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nam</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>A case of pityriasis lichenoides et varioliformis acuta after topical application of diphenylcyclopropenone.</article-title>
            <source>Eur J Dermatol</source>
            <year>2020</year>
            <month>Jun</month>
            <day>01</day>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-318</page-range>
            <pub-id pub-id-type="pmid">32540809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khachemoune</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blyumin</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Pityriasis lichenoides: pathophysiology, classification, and treatment.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2007</year>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-36</page-range>
            <pub-id pub-id-type="pmid">17298104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hood</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Histopathologic diagnosis of pityriasis lichenoides et varioliformis acuta and its clinical correlation.</article-title>
            <source>Arch Dermatol</source>
            <year>1982</year>
            <month>Jul</month>
            <volume>118</volume>
            <issue>7</issue>
            <fpage>478</fpage>
            <page-range>478-82</page-range>
            <pub-id pub-id-type="pmid">7092272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacarrubba</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Micali</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Dermoscopy of pityriasis lichenoides et varioliformis acuta.</article-title>
            <source>Arch Dermatol</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>146</volume>
            <issue>11</issue>
            <fpage>1322</fpage>
            <pub-id pub-id-type="pmid">21079087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clarey</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Lauer</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Trowbridge</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Clinical, Dermatoscopic, and Histological Findings in a Diagnosis of Pityriasis Lichenoides.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Jun</month>
            <day>20</day>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>e8725</fpage>
            <pub-id pub-id-type="pmid">32699720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henning</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Pityriasis lichenoides chronica.</article-title>
            <source>Dermatol Online J</source>
            <year>2004</year>
            <month>Nov</month>
            <day>30</day>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>8</fpage>
            <pub-id pub-id-type="pmid">15748578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellerbroek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pityriasis Lichenoides et Varioliformis Acuta: Remission with Hypopigmentation.</article-title>
            <source>J Pediatr</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>176</volume>
            <fpage>211</fpage>
            <page-range>211-211.e1</page-range>
            <pub-id pub-id-type="pmid">27301571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Antonov</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Lauren</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Morel</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Garzon</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Pityriasis Lichenoides in Childhood: Review of Clinical Presentation and Treatment Options.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2015</year>
            <season>Sep-Oct</season>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>579</fpage>
            <page-range>579-92</page-range>
            <pub-id pub-id-type="pmid">25816855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nofal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Assaf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alakad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nofal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yosef</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Febrile ulceronecrotic Mucha-Habermann disease: proposed diagnostic criteria and therapeutic evaluation.</article-title>
            <source>Int J Dermatol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>55</volume>
            <issue>7</issue>
            <fpage>729</fpage>
            <page-range>729-38</page-range>
            <pub-id pub-id-type="pmid">26695875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellinato</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maurelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gisondi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Girolomoni</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of treatments for pityriasis lichenoides.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>2039</fpage>
            <page-range>2039-2049</page-range>
            <pub-id pub-id-type="pmid">31318465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Oral erythromycin in pityriasis lichenoides chronica and pityriasis lichenoides et varioliformis acuta.</article-title>
            <source>Dermatol Ther</source>
            <year>2020</year>
            <month>May</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>e13311</fpage>
            <pub-id pub-id-type="pmid">32174014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinton</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Capezzera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Panfilis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Medium-dose ultraviolet A1 therapy for pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>410</fpage>
            <page-range>410-4</page-range>
            <pub-id pub-id-type="pmid">12196751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>ZG</given-names>
              </name>
            </person-group>
            <article-title>A case of pityriasis lichenoides et varioliformis acuta pemphigoides successfully treated with methotrexate and corticosteroids.</article-title>
            <source>Dermatol Ther</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>e12833</fpage>
            <pub-id pub-id-type="pmid">30659712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazaridou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fotiadou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tsorova</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trachana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trigoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patsatsi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ioannides</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Resistant pityriasis lichenoides et varioliformis acuta in a 3-year-old boy: successful treatment with methotrexate.</article-title>
            <source>Int J Dermatol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-7</page-range>
            <pub-id pub-id-type="pmid">20465649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsianakas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoeger</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Transition of pityriasis lichenoides et varioliformis acuta to febrile ulceronecrotic Mucha-Habermann disease is associated with elevated serum tumour necrosis factor-alpha.</article-title>
            <source>Br J Dermatol</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>152</volume>
            <issue>4</issue>
            <fpage>794</fpage>
            <page-range>794-9</page-range>
            <pub-id pub-id-type="pmid">15840118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meziane</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Caudron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dhaille</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jourdan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dadban</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lok</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chaby</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Febrile ulceronecrotic Mucha-Habermann disease: treatment with infliximab and intravenous immunoglobulins and review of the literature.</article-title>
            <source>Dermatology</source>
            <year>2012</year>
            <volume>225</volume>
            <issue>4</issue>
            <fpage>344</fpage>
            <page-range>344-8</page-range>
            <pub-id pub-id-type="pmid">23391565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreuter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Knispel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wieland</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Oellig</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tigges</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Complete resolution of febrile ulceronecrotic Mucha-Habermann disease following infliximab therapy.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>184</fpage>
            <page-range>184-6</page-range>
            <pub-id pub-id-type="pmid">26790133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jang</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Rim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Pityriasis Lichenoides-like Mycosis Fungoides: Clinical and Histologic Features and Response to Phototherapy.</article-title>
            <source>Ann Dermatol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>540</fpage>
            <page-range>540-547</page-range>
            <pub-id pub-id-type="pmid">27746631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144778.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomson</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Russell-Jones</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Charles-Holmes</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Childhood cutaneous T-cell lymphoma in association with pityriasis lichenoides chronica.</article-title>
            <source>Br J Dermatol</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>141</volume>
            <issue>6</issue>
            <fpage>1146</fpage>
            <page-range>1146-8</page-range>
            <pub-id pub-id-type="pmid">10722276</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
